Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

Keyphrases

• In(III) 100%
• Gemcitabine 100%
• Impaired Renal Function 100%
• Carboplatin 100%
• Bladder Transitional Cell Carcinoma 100%
• Hematotoxicity 66%
• Spain 33%
• Tumor 33%
• Disease Progression 33%
• Anemia 33%
• New Combination 33%
• Bladder Cancer 33%
• Elderly Patients 33%
• Thrombocytopenia 33%
• Locally Advanced 33%
• Renal Impairment 33%
• Non-surgical 33%
• Vomiting 33%
• Complete Response 33%
• Stable Disease 33%
• Partial Response 33%
• Neutropenic 33%
• Alopecia 33%
• Combination Therapy 33%
• Low Toxicity 33%
• Hepatic Toxicity 33%
• Creatinine Clearance 33%
• Renal Toxicity 33%
• Karnofsky Performance Status 33%
• Toxic Death 33%
• Granulocytopenia 33%
• Urinary Bladder Tumor 33%
• Area under the Concentration Curve 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Gemcitabine 100%
• Transitional Cell Carcinoma 100%
• Carboplatin 100%
• Nephrotoxicity 50%
• Disease 50%
• Neoplasm 50%
• Combination Therapy 50%
• Disease Exacerbation 50%
• Thrombocytopenia 50%
• Creatinine 50%
• Anemia 50%
• Alopecia 50%
• Bladder Cancer 50%
• Bladder Tumor 50%
• Granulocytopenia 50%